Gemini Therapeutics, Inc.
Gemini Therapeutics, Inc. (GMTX) Revenue
Annual & quarterly revenue history · segment & region breakdown
GMTX · revenue · updated Jun 9, 2026
Core revenue metrics
Trailing 12 monthsGemini Therapeutics, Inc. trailing twelve-month (TTM) revenue is $0.00B, an increase of 0.00% year-over-year from — in FY.
Revenue trend
– · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|
About Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income Gemini Therapeutics, Inc. receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
Gemini Therapeutics, Inc. reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.
Data sourced from Gemini Therapeutics, Inc.'s 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
GMTX revenue · 4 questionsGMTX's trailing twelve-month (TTM) revenue is $0.00B. That is an increase of 0.00% year-over-year from — in FY.
▸ Source: FMP · Gemini Therapeutics, Inc. SEC filings · GAAP · Gemini Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026